Discover Startup Events Near Me 

Wugen Raises $172M in Series B Funding

Wugen, a Sant Louis MO- and San Diego CA-based clinical stage biotechnology company, raised $172M in Series B funding. The round was led by Abingworth and Tybourne Capital Management with participation from Fidelity Management & Research Company, Intermediate Capital Group (ICG), Sands Capital, Aisling Capital Management, Alexandria Venture Investments, Velosity Capital, Falcon Edge Capital, RiverVest Venture Partners, LYZZ Capital, Lightchain Capital. Led by Dan Kemp, Wugen provides a clinical-stage biotechnology company developing a pipeline of off-the-shelf memory natural killer (NK) cell therapies to treat a broad range of hematological and solid tumor malignancies. In addition, the company is developing a pipeline of programs targeting solid tumor indications. FinSMEs17/07/2021

Startup Around is now on Telegram and Whatsapp. For the best startup stories & resources, subscribe us on Telegram & Whatsapp.